NOACs Added to WHO’s Essential Medicines List: Recommendations for Future Policy Actions
Open Access
- 6 October 2020
- journal article
- editorial
- Published by Ubiquity Press, Ltd. in CVD Prevention and Control
- Vol. 15 (1), 67
- https://doi.org/10.5334/gh.774
Abstract
The introduction of non-vitamin K antagonists oral anticoagulants, a class of medicines which includes dabigatran, apixaban, edoxaban and rivaroxaban, has resulted in improvements in the safety and efficacy of non valvular atrial fibrillation treatment for stroke prevention, with significant reductions in stroke, intracranial haemorrhage, and mortality. For these reasons, a team of World Heart Federation Emerging Leaders led efforts to add non-vitamin K antagonists oral anticoagulants to the World Health Organization's Model List of Essential Medicines in 2019. Following the inclusion of this class of medicines in the Essential Medicines List, this editorial proposes several recommendations to improve the accessibility, affordability and acceptability of non-vitamin K oral anticoagulants, especially in low- and middle-income settings, in order to successfully manage non-valvular atrial fibrillation and to lower the risk of stroke.Keywords
This publication has 24 references indexed in Scilit:
- Global Burden of Atrial Fibrillation in Developed and Developing NationsCVD Prevention and Control, 2014
- Edoxaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2013
- Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060European Heart Journal, 2013
- The Global Burden of Atrial Fibrillation and StrokeSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationThe New England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009
- Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial FibrillationAnnals of Internal Medicine, 2007
- Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future PrevalenceCirculation, 2006
- 25 years of the WHO essential medicines lists: progress and challengesThe Lancet, 2003